The breast cancer panel: a case-based discussion on the use of targeted therapies for primary and metastatic disease.
Fortenbaugh
Cathy
C
Pennsylvania Oncology Hematology Associates, Philadelphia, USA.
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D016903:Drug Monitoring; D005260:Female; D018734:Genes, erbB-2 / Q000235:genetics; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D024802:Nurse's Role; D009859:Oncology Nursing / Q000458:organization & administration; D010348:Patient Care Team / Q000458:organization & administration; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011788:Quality of Life; D015996:Survival Rate
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab